BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,636 | -46.8% | 215 | -36.2% | 0.00% | – |
| Q2 2023 | $27,509 | +147.2% | 337 | +124.7% | 0.00% | – |
| Q1 2023 | $11,128 | +11.0% | 150 | +24.0% | 0.00% | – |
| Q4 2022 | $10,029 | +0.3% | 121 | +245.7% | 0.00% | – |
| Q3 2022 | $10,000 | -54.5% | 35 | -45.3% | 0.00% | – |
| Q2 2022 | $22,000 | -4.3% | 64 | +23.1% | 0.00% | – |
| Q1 2022 | $23,000 | -56.6% | 52 | -49.0% | 0.00% | – |
| Q4 2021 | $53,000 | +8.2% | 102 | 0.0% | 0.00% | – |
| Q3 2021 | $49,000 | +6.5% | 102 | -1.0% | 0.00% | – |
| Q2 2021 | $46,000 | -16.4% | 103 | -28.5% | 0.00% | -100.0% |
| Q1 2021 | $55,000 | +5.8% | 144 | -11.7% | 0.00% | 0.0% |
| Q4 2020 | $52,000 | +30.0% | 163 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $40,000 | -4.8% | 163 | +3.2% | 0.00% | 0.0% |
| Q2 2020 | $42,000 | -37.3% | 158 | -55.2% | 0.00% | 0.0% |
| Q1 2020 | $67,000 | -18.3% | 353 | -5.9% | 0.00% | 0.0% |
| Q4 2019 | $82,000 | +134.3% | 375 | +108.3% | 0.00% | 0.0% |
| Q3 2019 | $35,000 | -7.9% | 180 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $38,000 | +5.6% | 180 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $36,000 | +38.5% | 180 | 0.0% | 0.00% | – |
| Q4 2018 | $26,000 | -85.6% | 180 | -79.5% | 0.00% | -100.0% |
| Q3 2018 | $180,000 | +15.4% | 880 | -16.7% | 0.00% | 0.0% |
| Q2 2018 | $156,000 | -45.3% | 1,056 | -44.0% | 0.00% | -40.0% |
| Q1 2018 | $285,000 | +14.5% | 1,887 | -1.7% | 0.01% | +25.0% |
| Q4 2017 | $249,000 | +1.6% | 1,919 | -5.4% | 0.00% | 0.0% |
| Q3 2017 | $245,000 | -2.4% | 2,029 | -5.1% | 0.00% | 0.0% |
| Q2 2017 | $251,000 | +22.4% | 2,138 | +6.0% | 0.00% | 0.0% |
| Q1 2017 | $205,000 | +15.8% | 2,017 | +17.0% | 0.00% | +33.3% |
| Q4 2016 | $177,000 | -34.7% | 1,724 | -30.3% | 0.00% | -40.0% |
| Q3 2016 | $271,000 | -16.9% | 2,475 | -14.5% | 0.01% | -37.5% |
| Q2 2016 | $326,000 | -3.6% | 2,895 | -14.2% | 0.01% | 0.0% |
| Q1 2016 | $338,000 | +9.0% | 3,375 | -2.0% | 0.01% | 0.0% |
| Q4 2015 | $310,000 | -5.2% | 3,445 | -2.7% | 0.01% | -11.1% |
| Q3 2015 | $327,000 | +2.2% | 3,541 | +8.9% | 0.01% | +12.5% |
| Q2 2015 | $320,000 | -5.3% | 3,251 | -3.7% | 0.01% | 0.0% |
| Q1 2015 | $338,000 | -1.5% | 3,375 | -9.0% | 0.01% | 0.0% |
| Q4 2014 | $343,000 | – | 3,708 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |